证券代码：300981 证券简称：中红医疗 公告编号：2025-107 中红普林医疗用品股份有限公司 关于子公司参与集中带量采购项目拟中选的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）控股子公司江西科伦 医疗器械制造有限公司（以下简称"科伦医械"）于近期参加江西省医用耗材带 量价格联动采购项目的投标工作。根据江西省医用耗材带量价格联动第一批带量 联动品种拟中选清单和采购需求量的公示结果显示，科伦医械部分产品拟中选上 述集中带量采购项目。现将相关情况公告如下： 品种分类 耗材型号规格 产品及注册证号 注册分类 适用范围 拟中选价 格及数量 拟供应 地区 一次性使 用输液用 肝素帽 HP-1 一次性使用输液用 肝素帽 国械注准 20163141530 Ⅲ类 本产品适用与静脉留 置针配合使用，为输 液 提 供 通 道 和 注 射 口。 中选数量 不对外公 开，中标价 格1.2元/ 个 江西省 一、拟中选产品基本情况 远发展产生积极影响。 三、风险提示 本次拟中选产品相关采购合同尚未签订，后续事项及对公司的影响 ...

中红普林医疗用品股份有限公司 关于公司及子公司2026年度向银行申请综合授信额度暨公 司为子公司申请综合授信额度提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、授信及担保情况概述 中红普林医疗用品股份有限公司（以下简称"公司"）于 2025 年 12 月 8 日召开第四届董事会第十五次会议，审议通过了《关于公司及子公司 2026 年度 向银行申请综合授信额度暨公司为子公司申请综合授信额度提供担保的议案》， 同意公司及控股子公司（包括 2026 年度新增的控股子公司）2026 年度向相关银 行申请综合授信额度合计不超过 50 亿元，最终以各家银行实际审批的授信额度 为准，其中以自有资产抵质押等方式向上述金融机构申请授信额度总额不超过人 民币 10 亿元，各抵质押主体可在总抵质押额度范围内使用；并同意公司为控股 子公司 2026 年度向金融机构申请的授信额度提供担保，担保额度总计不超过 25 亿元，其中，为资产负债率 70%（含）以上的控股子公司提供担保额度为不超过 15 亿元。 为便于实施上述向银行申请授信及担保事项，公司董事会提请股东会授权 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）第四届董事会第十 五次会议拟定于 2025 年 12 月 25 日（星期四）召开 2025 年第四次临时股东会， 会议有关事项通知如下： 一、召开会议的基本情况 1、股东会届次：2025年第四次临时股东会 证券代码：300981 证券简称：中红医疗 公告编号：2025-106 中红普林医疗用品股份有限公司 关于召开 2025 年第四次临时股东会的通知 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号—创业 板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章 程》的有关规定。 2、股东会的召集人：董事会 4、会议时间： （1）现场会议时间：2025年12月25日14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025年12月25日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所 互联网投票系统投票的具 ...

一、会议召开情况 中红普林医疗用品股份有限公司（以下简称"公司"）第四届董事会第十五 次会议于 2025 年 12 月 8 日以通讯方式召开，2025 年 12 月 3 日公司以电话和电 子邮件方式向全体董事发出会议通知。会议应出席董事 9 人，实际出席董事 9 人。会议由董事长桑树军先生主持，公司高级管理人员和相关人员列席了会议。 会议的召集、召开符合相关法律、法规和《公司章程》的规定。 证券代码：300981 证券简称：中红医疗 公告编号：2025-104 中红普林医疗用品股份有限公司 第四届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 二、会议审议情况 1.审议通过《关于公司及子公司 2026 年度向银行申请综合授信额度暨公司 为子公司申请综合授信额度提供担保的议案》 同意公司及控股子公司（包括 2026 年度新增的控股子公司）2026 年度向相 关银行申请综合授信额度合计不超过 50 亿元，最终以各家银行实际审批的授信 额度为准，其中以自有资产抵质押等方式向上述金融机构申请授信额度总额不超 过人民币 10 亿元，各抵质押主 ...

证券之星消息，截至2025年12月4日收盘，中红医疗(300981)报收于15.21元，上涨3.82%，换手率 4.84%，成交量19.02万手，成交额2.83亿元。 12月4日的资金流向数据方面，主力资金净流出1582.07万元，占总成交额5.59%，游资资金净流入 1205.2万元，占总成交额4.26%，散户资金净流入376.86万元，占总成交额1.33%。 近5日资金流向一览见下表： | 指标 | 中红医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 65.23亿元 | 109.58亿元 | 54 124 | | 净资产 | 55.08亿元 | 38.93亿元 | 25 124 | | 净利润 | -721.02万元 | 2.12亿元 | 100 124 | | 市盈率(动) | -678.53 | 60.57 | - 124 | | 市净率 | 1.22 | 3.81 | 14 124 | | 毛利率 | 10.54% | 51.22% | 123 124 | | 净利率 | -0.51% | 9.57% | 98 124 | | ROE ...

Core Viewpoint - The flu virus is becoming increasingly active in China as the autumn and winter temperatures drop, with the positive rate of flu-like cases nearing 45%, indicating a significant rise in respiratory infectious diseases [1] Group 1: Flu Activity and Prevention - The flu virus can spread through droplets and contact with contaminated surfaces, emphasizing the need for effective protective measures [1] - The Chinese Center for Disease Control and Prevention highlights the importance of hand protection in preventing the transmission of the flu virus [1] Group 2: Company Overview - Zhonghong Medical, a state-controlled listed company, is a leading player in the domestic medical protection sector, offering a comprehensive range of medical gloves to enhance health protection during the flu season [1][2] - The company provides various types of disposable protective gloves, including medical examination gloves and household protective gloves, catering to different scenarios from professional medical use to home care [2] Group 3: Product Features and Innovations - Zhonghong Medical's gloves are designed to meet industry standards and utilize innovative materials and processes to create a multi-layered hand protection system for flu prevention [2] - The company emphasizes the importance of proper glove usage, including the "one-use-one-change" principle, to minimize the risk of secondary contamination [2] Group 4: Future Focus and Product Expansion - In addition to disposable health protection gloves, Zhonghong Medical is expanding its product line to include condoms, safety infusion devices, wireless monitoring sensors, and other health-related products [2] - The company plans to focus on developing life support devices, surgical instruments, implantable devices, and assisted reproductive technology products in the future [2]

Group 1 - The core viewpoint of the article is that Zhonghong Medical (300981) is committed to leveraging its business and industry advantages while focusing on the healthcare sector [1] Group 2 - The actual controller of the company is the Xiamen State-owned Assets Supervision and Administration Commission [1] - The company is actively engaging with investors through interactive platforms to address inquiries [1]

Group 1 - The core viewpoint of the article highlights the role of Zhonghong Medical as a state-owned enterprise in Fujian, emphasizing its commitment to leveraging its business and industry advantages in the healthcare sector [1] - Zhonghong Medical is under the actual control of the Xiamen State-owned Assets Supervision and Administration Commission, which indicates strong governmental support [1] - The company expresses gratitude for investor interest and reiterates its focus on the medical and health industry [1]

Core Viewpoint - Zhonghong Medical (300981) is actively working to leverage its subsidiary's advantages in the context of the upcoming full closure of Hainan Free Trade Port, focusing on optimizing policy implementation, expanding market channels, and enhancing collaborative research and development [1] Group 1 - The company is responding to investor inquiries regarding the potential benefits of Hainan Free Trade Port's full closure for its subsidiary, Zhonghong Medical Supplies (Hainan) Co., Ltd [1] - The company aims to maximize the advantages of its subsidiary's location and industry through strategic initiatives [1] - The company expresses gratitude for investor interest and emphasizes its commitment to innovative development [1]

Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4554.17 points, up 0.2%, with a trading volume of 7.409 billion yuan and a turnover rate of 0.81% [1] - Among the index constituents, 38 stocks rose while 17 fell, with Yidu Technology leading the gainers at 3.5% and Mylab leading the decliners at 4.98% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56% and a latest price of 201.62, down 1.17% [1] - Aier Eye Hospital (sz300015) with a weight of 11.62% and a latest price of 11.57, up 0.61% [1] - Lepu Medical (sz300003) with a weight of 4.85% and a latest price of 16.00, up 0.38% [1] - Aimeike (sz300896) with a weight of 4.80% and a latest price of 146.00, up 0.43% [1] - Yuyue Medical (sz002223) with a weight of 4.66% and a latest price of 36.25, up 1.54% [1] - Yingke Medical (sz300677) with a weight of 3.64% and a latest price of 43.48, up 0.95% [1] - Furuide (sz300049) with a weight of 3.59% and a latest price of 69.38, up 2.53% [1] - Meinian Health (sz002044) with a weight of 3.58% and a latest price of 5.27, down 1.50% [1] - Sinopharm (hk01099) with a weight of 3.35% and a latest price of 18.58, up 2.00% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63% and a latest price of 13.53, up 1.22% [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 172 million yuan, while retail funds saw a net inflow of approximately 84.92 million yuan [3] - Notable capital flows include: - Sanbo Brain Science (301293) with a main fund net inflow of 26.77 million yuan [3] - Ruimait (301367) with a main fund net inflow of 16.21 million yuan [3] - Chutian Technology (300358) with a main fund net inflow of 11.20 million yuan [3] - The index constituents underwent an adjustment with one new stock added in the last ten days [3]